Skip to main content
OpenTrials
Completed

NCT Number: NCT02180516

Safety and Efficacy of Meloxicam Compared to Other Nonsteroidal Antiinflammatory Drugs (NSAIDs) in an Observational Cohort Study of Patients With Rheumatoid Arthritis, Osteoarthritis, Lumbago, Scapulohumeral Periarthritis, Neck, Shoulder and Arm Syndrome

Study to assess the safety profile of meloxicam by comparing incidence of gastrointestinal adverse events of meloxicam with that of NSAID in the routine daily therapeutic situation.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Arthritis, Rheumatoid Arthritis Autoimmune Diseases Connective Tissue Diseases Immune System Diseases Joint Diseases Musculoskeletal Diseases Rheumatic Diseases Skin and Connective Tissue Diseases

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with Indications according to the package insert of the prescribed NSAID

Exclusion criteria

  • There is no exclusion criterion, because this Post Marketing Study is an observational study

Treatment and study plan

Meloxicam

Drug

Other Non Steroidal Anti-Inflammatory Drugs (NSAIDs) except etodolac

Drug

Primary outcomes

  1. Incidence for adverse event of gastrointestinal disorder

    Time frame: up to 6 months

Secondary outcomes

  1. Incidence for adverse drug reaction of gastrointestinal disorder

    Time frame: up to 6 months

  2. Incidence of adverse events

    Time frame: up to 6 months

  3. Incidence of adverse drug reactions

    Time frame: up to 6 months

  4. Incidence of serious adverse events

    Time frame: up to 6 months

  5. Incidence for adverse events Perforation, Ulcer and Bleeding (PUB) in the upper gastrointestinal tract

    Time frame: up to 6 months

Sponsors and collaborators

Lead sponsor

Boehringer Ingelheim

Industry

Registry information

Official study title

Safety and Efficacy of Meloxicam (MOBIC) Compared to Other NSAIDs in Approved Therapeutic Dosages and Routes of Administration in an Observational Cohort Study of Patients With Rheumatoid Arthritis, Osteoarthritis, Lumbago, Scapulohumeral Periarthritis, Neck, Shoulder and Arm Syndrome

Important dates

Study start
2001
Primary completion
2004
First posted
Jul 2, 2014
Registry last updated
Jul 8, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.